Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Raw Materials: 2011-2017

Historic Raw Materials for Anika Therapeutics (ANIK) over the last 7 years, with Dec 2017 value amounting to $11.3 million.

  • Anika Therapeutics' Raw Materials rose 68.31% to $13.2 million in Q3 2018 from the same period last year, while for Sep 2018 it was $13.2 million, marking a year-over-year increase of 68.31%. This contributed to the annual value of $11.3 million for FY2017, which is 91.98% up from last year.
  • Anika Therapeutics' Raw Materials amounted to $11.3 million in FY2017, which was up 91.98% from $5.9 million recorded in FY2016.
  • Anika Therapeutics' 5-year Raw Materials high stood at $11.3 million for FY2017, and its period low was $5.8 million during FY2015.
  • Over the past 3 years, Anika Therapeutics' median Raw Materials value was $5.9 million (recorded in 2016), while the average stood at $7.7 million.
  • In the last 5 years, Anika Therapeutics' Raw Materials dropped by 6.20% in 2015 and then spiked by 91.98% in 2017.
  • Over the past 5 years, Anika Therapeutics' Raw Materials (Yearly) stood at $5.9 million in 2013, then increased by 3.98% to $6.2 million in 2014, then dropped by 6.20% to $5.8 million in 2015, then increased by 1.80% to $5.9 million in 2016, then soared by 91.98% to $11.3 million in 2017.